- Home
- PLTR vs ABBV Comparison
PLTR vs ABBV Comparison
Compare PLTR & ABBV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLTR
- ABBV
- Stock Information
- Founded
- PLTR 2003
- ABBV 2012
- Country
- PLTR United States
- ABBV United States
- Employees
- PLTR N/A
- ABBV 55000
- Industry
- PLTR Retail: Computer Software & Peripheral Equipment
- ABBV Biotechnology: Pharmaceutical Preparations
- Sector
- PLTR Technology
- ABBV Health Care
- Exchange
- PLTR Nasdaq
- ABBV Nasdaq
- Market Cap
- PLTR 364.9B
- ABBV 337.1B
- IPO Year
- PLTR 2020
- ABBV N/A
- Fundamental
- Price
- PLTR $158.80
- ABBV $190.36
- Analyst Decision
- PLTR Hold
- ABBV Buy
- Analyst Count
- PLTR 20
- ABBV 22
- Target Price
- PLTR $99.11
- ABBV $213.14
- AVG Volume (30 Days)
- PLTR 67.7M
- ABBV 6.6M
- Earning Date
- PLTR 08-04-2025
- ABBV 07-31-2025
- Dividend Yield
- PLTR N/A
- ABBV 3.45%
- EPS Growth
- PLTR 92.54
- ABBV N/A
- EPS
- PLTR 0.23
- ABBV 2.34
- Revenue
- PLTR $3,115,024,000.00
- ABBV $57,367,000,000.00
- Revenue This Year
- PLTR $38.89
- ABBV $8.47
- Revenue Next Year
- PLTR $28.59
- ABBV $8.22
- P/E Ratio
- PLTR $688.92
- ABBV $81.34
- Revenue Growth
- PLTR 33.45
- ABBV 5.45
- 52 Week Low
- PLTR $21.23
- ABBV $163.81
- 52 Week High
- PLTR $160.38
- ABBV $218.66
- Technical
- Relative Strength Index (RSI)
- PLTR 68.84
- ABBV 52.52
- Support Level
- PLTR $145.06
- ABBV $184.63
- Resistance Level
- PLTR $155.44
- ABBV $192.24
- Average True Range (ATR)
- PLTR 4.73
- ABBV 4.17
- MACD
- PLTR 0.70
- ABBV -0.04
- Stochastic Oscillator
- PLTR 93.54
- ABBV 44.52
About PLTR Palantir Technologies Inc.
Palantir is an analytical software company that focuses on leveraging data to create efficiencies in its clients' organizations. The firm serves commercial and government clients via its Foundry and Gotham platforms, respectively. Palantir works only with entities in Western-allied nations and reserves the right not to work with anyone that is antithetical to Western values. The Denver-based company was founded in 2003 and went public in 2020.
About ABBV AbbVie Inc.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).